CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/
临床试验:皮下重组 IL-2 在患者中的 III 期研究
基本信息
- 批准号:7717012
- 负责人:
- 金额:$ 2.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-12-01 至 2008-11-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAdultAldesleukinAnti-HIV AgentsAnti-Retroviral AgentsAntiviral TherapyCD4 Lymphocyte CountCD4 Positive T LymphocytesCellsClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseDiseaseDrug CombinationsFailureFundingGrantHIVHIV InfectionsImmuneInfectionInjection of therapeutic agentInstitutionInterleukin-2Investigational DrugsLifeLocationMaintenancePatientsPhaseRecombinantsResearchResearch PersonnelResourcesSafetySex BehaviorSkinSourceTherapeutic InterventionUnited States National Institutes of HealthViralageddayfight againstfollow-uppurgesubcutaneous
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
A trial to determine if the use of subcutaneous (under the skin) proleukin (IL-2) results in higher CD4 cell counts in patients infected with HIV, but having a CD4 count less than 300/mm3.
Worldwide, approximately one in every 100 adults aged 15-49 is HIV infected. This is an estimated 33.4 million people living with HIV/AIDS. Even though educational efforts to modify sexual behaviors have resulted in a decline of HIV infection in some locations, the prediction is that as many as 16,000 people will become infected each day.
Much progress has been made in understanding the disease and in implementing potent therapeutic interventions. However, these potent antiretroviral drug combinations do not result in viral eradication and cannot guarantee maintenance of viral control. Thus, treatment must be continuously changed. Among patients with apparent virologic control, a "ceiling effect" seems to exist with failure of CD4+ cell counts to rise on an average of more than 100 to 150 cells/mm3, at least during the first two years. CD4 cells are immune cells that fight against infection. It has recently been speculated that proleukin, in combination with potent antiviral therapy may be a useful approach for purging HIV from the latently infected CD4+ cells.
Proleukin is an investigational drug. Subjects in this study have participated in a previous IL-2 study and will enter this study as a follow-up. Several studies have shown that an injection of IL-2 under the skin can increase CD4+ cell counts in most subjects. This study will see if IL-2, in combination with anti-HIV drugs, can cut down on serious infections and prolong the lives of these patients. It will also determine the safety of IL-2 over several years.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
一项试验,以确定使用皮下(皮肤下)白介素(IL-2)是否会导致感染HIV但CD 4计数低于300/mm 3的患者的CD 4细胞计数升高。
在全世界,每100名15至49岁的成年人中约有一人感染艾滋病毒。估计有3 340万人感染艾滋病毒/艾滋病。尽管改变性行为的教育努力已经导致一些地区的艾滋病毒感染率下降,但预测每天将有多达16,000人被感染。
在了解这种疾病和实施有效的治疗干预措施方面取得了很大进展。然而,这些有效的抗逆转录病毒药物组合不会导致病毒根除,并且不能保证维持病毒控制。因此,治疗必须不断改变。在明显病毒学控制的患者中,似乎存在“天花板效应”,至少在头两年,CD 4+细胞计数平均不能上升超过100至150个细胞/mm 3。CD 4细胞是抵抗感染的免疫细胞。最近有人推测,proleukin与有效的抗病毒治疗相结合,可能是一种有用的方法,用于清除潜伏感染的CD 4+细胞中的HIV。
Proleukin是一种研究药物。本研究中的受试者已参与既往IL-2研究,并将进入本研究作为随访。几项研究表明,在皮肤下注射IL-2可以增加大多数受试者的CD 4+细胞计数。这项研究将观察IL-2与抗HIV药物的结合是否可以减少严重感染并延长这些患者的生命。它还将在几年内确定IL-2的安全性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL W NIXON其他文献
DANIEL W NIXON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL W NIXON', 18)}}的其他基金
START- STRATEGIC TIMING OF ANTIRETROVIRAL THERAPY
开始——抗逆转录病毒治疗的战略时机
- 批准号:
8166579 - 财政年份:2009
- 资助金额:
$ 2.71万 - 项目类别:
STUDY A5235: A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN THE
研究 A5235:米诺环素的 II 期、随机、双盲研究
- 批准号:
8166560 - 财政年份:2009
- 资助金额:
$ 2.71万 - 项目类别:
CLINICAL TRIAL: A PHASE III COMPARATIVE STUDY OF THREE NON-NUCLEOSIDE REVERSE TR
临床试验:三种非核苷反向TR的III期比较研究
- 批准号:
8166580 - 财政年份:2009
- 资助金额:
$ 2.71万 - 项目类别:
CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/
临床试验:皮下重组 IL-2 在患者中的 III 期研究
- 批准号:
7950848 - 财政年份:2008
- 资助金额:
$ 2.71万 - 项目类别:
AN INTERNATIONAL, PHASE II, MULTI-SITE, OPEN-LABEL, RANDOMIZED STUDY OF ALDES
ALDES 的国际、II 期、多中心、开放标签、随机研究
- 批准号:
7717048 - 财政年份:2007
- 资助金额:
$ 2.71万 - 项目类别:
NUTRITIONAL INTAKE, HORMONE LEVELS, ENERGY BALANCE AND BREAST CANCER NATURAL HX
营养摄入量、激素水平、能量平衡和乳腺癌 NATURAL HX
- 批准号:
6119059 - 财政年份:1998
- 资助金额:
$ 2.71万 - 项目类别:
BIOAVAILABILITY STUDY OF ELLAGIC ACID FROM DIETARY INTAKE OF RASPBERRIES
覆盆子膳食摄入中鞣花酸的生物利用度研究
- 批准号:
6250279 - 财政年份:1997
- 资助金额:
$ 2.71万 - 项目类别:
NUTRITIONAL INTAKE, HORMONE LEVELS, ENERGY BALANCE AND BREAST CANCER NATURAL HX
营养摄入量、激素水平、能量平衡和乳腺癌 NATURAL HX
- 批准号:
6250289 - 财政年份:1997
- 资助金额:
$ 2.71万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 2.71万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 2.71万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 2.71万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 2.71万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 2.71万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)